This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

Repros Therapeutics Inc.(R) Reports Fourth Quarter And Year End 2012 Financial Results

THE WOODLANDS, Texas, March 18, 2013 (GLOBE NEWSWIRE) -- Repros Therapeutics Inc. ® (Nasdaq:RPRX) today announced financial results for the quarter and year ended December 31, 2012.

Liquidity and Capital Resources

The Company had cash and cash equivalents of approximately $24.2 million as of December 31, 2012 as compared to $4.6 million as of December 31, 2011. Net cash of approximately $13.5 million was used in operating activities during the year ended December 31, 2012 as compared to $9.8 million for the year ended December 31, 2011. The major use of cash during 2012 was to fund the Company's clinical development programs and associated administrative costs. Cash used in investing activities during 2012 was approximately $608,000 primarily for capitalized patent and patent application costs for Androxal ® and Proellex ®. Cash provided by financing activities during 2012 was approximately $33.8 million primarily due to the registered direct offering of 2,463,537 shares of our common stock at a price per share of $4.50 completed on February 1, 2012 and the private placement of 2,145,636 shares of our common stock at a price per share of $11.00 completed on September 7, 2012.  

Financial Results

Net loss for the three month period ended December 31, 2012, was ($8.0) million or ($0.47) per share as compared to a net loss of ($2.7) million or ($0.22) per share for the same period in 2011. The net loss for the twelve month period ended December 31, 2012, was ($18.2) million or ($1.18) per share as compared to a net loss of ($12.5) million or ($1.04) per share for the same period in 2011. The increase in loss for both the three and twelve month periods ended December 31, 2012 as compared to the same periods in 2011 was primarily due to increased expenses in clinical development related to Androxal ® and Proellex ® and payroll and benefits.            

Research and development ("R&D") expenses increased 54% or approximately $4.7 million to $13.3 million for the year ended December 31, 2012 as compared to $8.7 million for the same period in the prior year. The increase in R&D expenses for the year ended 2012 as compared to 2011 is primarily due to an increase of $3.4 million in clinical development expenses related to the Phase 3 studies for Androxal ®. Clinical development expenses for Proellex ® increased approximately $768,000 for the year ended 2012 as compared to 2011 due to the Phase 2 vaginal administration study for uterine fibroids conducted in 2012. Payroll and benefits expenses increased for the year ended 2012 as compared to 2011 by $830,000 due to increased headcount. Included in payroll and benefits expenses is a charge for non-cash stock based compensation of $880,000 for the year ended 2012 as compared to $540,000 in 2011. Additionally, operating and occupancy expenses decreased $335,000 for the year ended 2012 as compared to 2011 due to decreased costs related to the Company's patent portfolio and a reduction in our product liability insurance premium.

General and administrative ("G&A") expenses increased 27% or approximately $1.0 million to $4.8 million for the year ended December 31, 2012 as compared to $3.8 million for the same period in the prior year. The increase in G&A expenses for 2012 as compared to 2011 is primarily due to an increase in payroll and benefits in the amount of $717,000. Included in payroll and benefit expense is a charge for non-cash stock based compensation expense of $1.9 million for 2012 as compared to $1.7 million in 2011. Additionally, salaries increased for the year ended 2012 by $526,000 as compared to 2011 due to an increase in headcount and the discontinuation of the salary reduction program put in place in August 2009. G&A operating and occupancy expenses, which include expenses to operate as a public company, increased for the year ended 2012 by approximately $299,000 as compared to 2011 due to an increase in professional services.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,203.37 -85.26 -0.47%
S&P 500 2,107.78 -9.61 -0.45%
NASDAQ 4,979.9010 -28.1950 -0.56%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs